Opendata, web and dolomites

MEISi SIGNED

Druggable Small Molecule Inhibitor of MEIS Proteins

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEISi project word cloud

Explore the words cloud of the MEISi project. It provides you a very rough idea of what is the project "MEISi" about.

class    71    significance    small    pct    cvds    pending    channels    benefit    noncommunicable    markets    prestigious    strategies    customers    deep    drug    company    feasibility    meis    validated    benchmarking    inhibitors    critical    inhibits    therapeutics    global    protein    selective    usd    accounting    indicate    tech    druggable    29    globally    risk    motivates    oncology    tackling    co    substance    efforts    active    ncds    deaths    never    plays    conduct    cancer    proteins    owing    44    competitive    commercialization    diseases    share    strategy    cardiovascular    biology    nearly    hoxa9    innovative    tgif2    molecule    metabolism    nature    3b    stem    family    countries    mechanisms    performing    segment    tools    pharmaceutically    entry    journals    sizes    molecular    meinox    ending    proper    national    ingredients    market    plan    first    discovery    massive    startup    regulations    deadliest    pbx    cell    published    diabetes    patented    10m    2018    modulate    meisi   

Project "MEISi" data sheet

The following table provides information about the project.

Coordinator
MEINOX ILAC TEKNOLOJILERI AS 

Organization address
address: RESITPASA MAH. KATAR CAD. TEKNOKENT ARI 1 NO: 2/5 ICKAPI NO: 19
city: SARIYER ISTANBUL
postcode: 34467
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEINOX ILAC TEKNOLOJILERI AS TR (SARIYER ISTANBUL) coordinator 50˙000.00

Map

 Project objective

MEISi is the first innovative product of Meinox as a druggable substance, owing to its years of research on MEIS biology (published in prestigious journals like Nature and Cell Stem Cell, and PCT patented - pending national entry in 44 countries). Meinox targets the deadliest noncommunicable diseases (NCDs); cancer, CVDs and diabetes, together accounting for nearly 71% of all deaths globally. Never ending efforts and global targets in tackling these diseases show the importance of the development of more effective therapeutics.

MEISi is a druggable target-based small molecule, developed and validated by Meinox. MEISi inhibits the activity of MEIS protein which plays a critical role in cell metabolism and associated with NCDs. The benefit it presents to the targeted drug discovery market is to provide tools to modulate molecular mechanisms of the NCDs. The massive sizes of oncology and cardiovascular drug markets (USD $ 29.3B globally) indicate the significance of the small molecule drug discovery market which motivates Meinox to target €10M market share in 3 years after commercialization.

Meinox is a deep-tech startup established in 2018 with the main focus on novel and high-level pharmaceutically active ingredients. The company aims to research, develop, produce and market first-in-class, selective drug-like small molecule inhibitors of MEIS, PBX and TGIF2 proteins and their co-factor HOXA9.

Meinox aims to conduct a feasibility study with a risk analysis based on different market regulations. In order to improve the commercialization plan, potential customers of MEISi will be identified and strategies will be developed for each segment by defining proper channels for the MEISi product family. Market entry strategy will be validated by performing market analysis and competitive benchmarking in the target markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEISI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEISI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More